Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Christopher LaGanke | Researchclopedia

Back to researchers

Christopher LaGanke

North Central College

53

Works

1,179

Citations

14

h-index

16

i10-index

Research Topics

Multiple Sclerosis Research Studies Polyomavirus and related diseases Mycobacterium research and diagnosis

Affiliations

Biogen (United States)2015–2015

Cleveland Clinic2015–2015

Virginia Mason Medical Center2015–2015

MultiCare Health System2012–2012

Carolinas Healthcare System2019–2019

Top Works

Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

Daniel S. Reich,Douglas L. Arnold,et al.

2021180 citations

Systemic Lupus Erythematosus Research

Peripheral Neuropathies and Disorders

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

Diego Cadavid,Michelle Mellion,et al.

2019177 citations

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

John Foley,Gilles Defer,et al.

2022106 citations

Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial

Tanuja Chitnis,Brenda Banwell,et al.

202179 citations

Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study

Robert T. Naismith,Jerry S. Wolinsky,et al.

201962 citations

Safety/tolerability of the anti-semaphorin 4D antibody VX15/2503 in a randomized phase 1 trial

Christopher LaGanke,Lawrence Samkoff,et al.

201761 citations

Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study

Tjalf Ziemssen,Ann Bass,et al.

202056 citations

Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management

Adam Cuker,Ann Bass,et al.

201954 citations

Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

Alasdair Coles,Joanne Jones,et al.

202124 citations